Quantification of the association between the intake of selenium and risk of pancreatic cancer is still conflicting. Thus, we conducted a meta-analysis to summarize the evidence from epidemiological studies of selenium intake with the risk of pancreatic cancer. Pertinent studies were identified by a search of PubMed and Web of Knowledge to July 2016. The random-effect model was used. Sensitivity analysis and publication bias were conducted. Data from six studies including 1424 pancreatic cancer cases were used in this meta-analysis. Pooled results suggested that highest selenium intake amount compared with lowest amount was significantly associated with the risk of pancreatic cancer [summary relative risk (RR)=0.659, 95% confidence interval (CI)=0.489–0.889, I2=47.6%]. The associations were significant both in case–control studies [RR=0.618, 95%CI=0.399–0.956, I2=59.1%] and Americas [RR=0.570, 95%CI=0.357–0.909, I2=65.6%]. No publication bias was found. Our analysis suggested that the higher intake of selenium might reduce the risk of pancreatic cancer.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: